IL17A and achondroplasia: Many scholars now believe that ACH is a subtype of pustular psoriasis, and that the immune system and the interleukin (IL)-17/IL-23 axis play key roles in the pathogenic mechanism, so the treatment of ACH is guided by its similarity to pustular psoriasis, and therefore IL-12/23 inhibitors and IL-23 inhibitors appear to be a promising option for the treatment of ACH (33, 34).